by: Parent Project Muscular Dystrophy
NS Pharma, Inc. has announced the launch of the viltolarsen Expanded Access Program in the United States for patients with Duchenne muscular dystrophy who are amenable to exon 53 skipping therapy and meet other eligibility criteria.
Read NS Pharma’s Press Release
Expanded Access Program Launched for Viltolarsen, an Investigational Exon 53 Skipping Antisense Oligonucleotide
PARAMUS, NJ: March 9, 2020 – NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President Shigenobu Maekawa), announced the launch of the viltolarsen Expanded Access Program in the United States for patients with Duchenne Muscular Dystrophy (DMD) who are amenable to exon 53 skipping therapy and meet other eligibility criteria.
NS Pharma has a strong commitment to the DMD community. DMD is a serious and lifethreatening disease for which there are limited treatment options. This viltolarsen Expanded Access Program will allow eligible patients to receive viltolarsen while it remains an investigational drug under FDA review. Viltolarsen has not yet been approved by any regulatory authority and its safety and effectiveness has not been established. NS Pharma is pleased to launch this program and remains committed to continuing to study the efficacy and safety of viltolarsen in patients with DMD amenable to exon 53 skipping therapy.
To inquire about participation in the viltolarsen Expanded Access program, physicians must make a request on behalf of their patient to NS Pharma, where each case will be reviewed for eligibility to participate. Physicians may email nspharma.expandedaccess@earlyaccesscare.com for more information on the viltolarsen Expanded Access Program.
